Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.
Also called NCT02610868
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 187 participants
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
- Registry
-
NCT02610868
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belarus, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02610868. Allocation not applicable; no masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2017-06 (actual). Results posted on 2019-11-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
- Acronym
- OPTIMYST
- Condition
- Sialorrhea
- Intervention (Drug)
- MYOBLOC
- Lead sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Record details
- Record id
cardio:ct-nct02610868- Content hash
6bee95c493b50cc5a6714c1765ce3ac7e4b57bd09c2c2aaf94f555ae2dcdc558